Abstract 1492P
Background
Due to the widespread uptake of 6-weekly Pembrolizumab (6wklyP) in the COVID-19 era, this audit attempts to clarify differences in clinically relevant immune therapy related adverse events (irAEs) between 6wklyP and traditional 3-weekly Pembrolizumab (3wklyP).
Methods
Oncology patients at the Gold Coast University Hospital with Advanced Melanoma or Metastatic Non-small cell lung cancer (NSCLC) who received single agent 3wklyP 200mg, 6wklyP 400mg or those who sequentially received 3wklyP followed by 6wklyP between 2017-2022 were analysed for frequency of clinically significant (Grade3-4) irAEs. Total time of immunosuppression for treatment of irAEs was recorded. Data was extracted from the electronic medical record and analysed using Cox-proportion hazard analysis.
Results
In total, 69 and 112 patients received 6wklyP and 3wklyP respectively. There were 52 patients with Melanoma and 129 patients with NSCLC. 30 patients received sequential treatment. Average observation time for toxicity was 327 days for 6wklyP and 352 days for 3wklyP. 17/69 (24.6%) patients who received 6wklyP developed Grade 3-4 irAEs compared with 9/112 (8%) 3wklyP patients (HR of 3.03; CI 1.34-6.83, p= 0.007). Grade 1-4 irAEs were 32/69 (46.4%) with 6wklyP and 31/112 (27.7%) with 3wklyP. 6/30 (20%) patients who received 6wklyP after initially receiving 3wklyP had Grade 3-4 irAEs (HR 0.56, CI 0.24-1.37; p= 0.187). Mean immunosuppression time for treatment of Grade 3-4 irAEs for 6wklyP and 3wklyP was 91 days and 55 days respectively (p =0.76). 6/17 (35.3%) 6wklyP patients required Steroid sparing agents to treat their Grade3-4 irAEs compared to 1/9 (11.1%) 3wklyP patients.
Conclusions
6wklyP was associated with significantly higher immune therapy related adverse events than 3wklyP. Sequential delivery of 6wklyP after 3wklyP did not significantly alter clinically significant adverse effects. Immunosuppressive management of irAEs were not statistically different between arms however there was a higher rate of steroid sparing immunomodulation requirement with 6wklyP.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1499P - Wnt5-ROR2 signalling mediated resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Etienne Giroux-Leprieur
Session: Poster session 21
1500TiP - REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design
Presenter: Ehsan Ghorani
Session: Poster session 21
1502TiP - A phase I/IIa trial of ChAdOx1 and MVA vaccines against MAGE-A3 and NY-ESO-1
Presenter: Fiona Blackhall
Session: Poster session 21
1503TiP - A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50%
Presenter: Mark Awad
Session: Poster session 21
1504TiP - HARMONi: Randomized, double-blind, multi-center, phase III clinical study of ivonescimab or placebo combined with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have progression following EGFR-TKI treatment
Presenter: WenFeng Fang
Session: Poster session 21
1505TiP - TROPION-Lung07: A phase III trial of datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy in advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 expression
Presenter: Isamu Okamoto
Session: Poster session 21
1506TiP - A single-arm, phase II study of amivantamab (AMI), lazertinib (L) and pemetrexed (P) for first-line treatment of recurrent/metastatic non-small cell lung cancers (NSCLCS) with epidermal growth factor receptor mutations in Exons 19 or 21 (EGFR 19/21): AMIGO 1 (LACOG0821)
Presenter: William Nassib William Junior
Session: Poster session 21
1507TiP - Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
Presenter: David Planchard
Session: Poster session 21
1508TiP - The 1920-EORTC-BIORADON study: Molecular characterization of non-small cell lung cancer (NSCLC) and indoor radon exposure in Europe
Presenter: Laura Mezquita
Session: Poster session 21